LONDON and BOSTON, Sep 10, 2014 (PR Newswire Europe via COMTEX) -- LONDON and BOSTON, September 10, 2014 /PRNewswire/ --
Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, notes that members of its senior management team will present at the following industry events:
7th CNS Partnering & Deal-making Conference [https://www.gtcbio.com/conferences/cns-partnering-and-deal-making-overview ] (San Francisco, CA, USA, 18-19 September)
Daniel Grau, Heptares President, will give a Keynote speech entitled “Neuroscience from the Vantage of Emerging Biotech” in which he will discuss strategies that are available to emerging companies for building a CNS product franchise while also removing or mitigating the risks of CNS drug development. The talk will take place on 18 September at 8:20am Pacific Daylight Time (PDT).
Mr Grau is also chairing a panel discussion on “CNS Licensing Strategies” on 19 September at 9:20am PDT.
BioPharm America 2014 [http://www.ebdgroup.com/bpa/index.php ]
Mr Grau will participate in a panel discussion entitled “Mayflower II: The migration of European biotechs to the US” which takes place on 22 September at 1:30pm EDT.
In addition, Malcolm Weir, Heptares CEO, will present an overview of the Company on 24 September at 9:45am EDT in Wellesley, Level 3.
For a full list of events at which Heptares will be present, please visit www.heptares.com [http://www.heptares.com ]
About Heptares Therapeutics
Heptares creates new medicines targeting clinically important, yet historically challenging, GPCRs (G protein-coupled receptors), a superfamily of drug receptors linked to a wide range of human diseases. Leveraging our proprietary structure-based drug design technology platform, we have built an exciting pipeline of novel drug candidates with the potential to transform the treatment of serious diseases, including Alzheimer’s disease, ADHD, diabetes, schizophrenia, and migraine. Our pharmaceutical partners include Cubist, MorphoSys, Takeda, AstraZeneca and MedImmune, and we are backed by Clarus Ventures, MVM Life Science Partners, Novartis Venture Fund, the Stanley Family Foundation and Takeda Ventures. To learn more about Heptares, please visit www.heptares.com [http://www.heptares.com ]
HEPTARES is a registered trademark in the EU, Switzerland, US and Japan.
StaR is a registered trademark in the EU and Japan.
CONTACT:
Contact Information: Citigate Dewe Rogerson (for Heptares) - MarkSwallow, Chris Gardner, +44-(0)20-7282-2948/2995,mark.swallow@citigatedr.co.uk. Heptares Therapeutics Ltd - Malcolm Weir,Chief Executive Officer (UK), +44-(0)1707-358-629,malcolm.weir@heptares.com; Dan Grau, President (USA), +1-857-222-4586,dan.grau@heptares.com Help employers find you! Check out all the jobs and post your resume. Copyright (C) 2014 PR Newswire Europe
